Vu Le

Array ( [id] => 18709539 [patent_doc_number] => 20230332158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => NOVEL USE OF HIC-5 INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/793837 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20232746 [patent_doc_number] => 20250290065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-18 [patent_title] => METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN [patent_app_type] => utility [patent_app_number] => 17/769524 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16748839 [patent_doc_number] => 20210100848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => METHODS AND COMPOSITIONS FOR HEMATOPOIETIC STEM CELL MOBILIZATION [patent_app_type] => utility [patent_app_number] => 17/065364 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091326 [patent_doc_number] => 20220409667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => TREATMENT OF CHRONIC GRANULOMATOUS DISEASE [patent_app_type] => utility [patent_app_number] => 17/765172 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20633437 [patent_doc_number] => 12594301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-07 [patent_title] => Compositions and methods for treatment of liquid cancers [patent_app_type] => utility [patent_app_number] => 17/762690 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 78 [patent_no_of_words] => 153752 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 209 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20562018 [patent_doc_number] => 12564608 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => Use of ghost nanovesicles as therapeutics [patent_app_type] => utility [patent_app_number] => 17/642140 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 4290 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511563 [patent_doc_number] => 20200390820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => ISOLATION, CULTIVATION AND USES OF STEM/PROGENITOR CELLS [patent_app_type] => utility [patent_app_number] => 17/006257 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034603 [patent_doc_number] => 20220378818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => OLIGONUCLEOTIDE-BASED THERAPY FOR ULCERATIVE COLITIS [patent_app_type] => utility [patent_app_number] => 17/636317 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426844 [patent_doc_number] => 20220054552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => Cellular pharmaceutical product containing quantified doubling level stem cells and a method for producing it [patent_app_type] => utility [patent_app_number] => 16/996924 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17799046 [patent_doc_number] => 11413313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Pharmaceutical composition for preventing or treating atopic dermatitis comprising clonal stem cells [patent_app_type] => utility [patent_app_number] => 16/992825 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 45 [patent_no_of_words] => 16847 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482437 [patent_doc_number] => 20200376037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => STEM CELL PREPARATION RESISTING HYPOXIA INJURY, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ACUTE MYOCARDIAL INFARCTION [patent_app_type] => utility [patent_app_number] => 16/991902 [patent_app_country] => US [patent_app_date] => 2020-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19374121 [patent_doc_number] => 12065671 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-20 [patent_title] => Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells [patent_app_type] => utility [patent_app_number] => 16/931003 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 28 [patent_no_of_words] => 21439 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16931003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567381 [patent_doc_number] => 20230257713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => IMMUNOTHERAPY METHOD OF TARGETED CHEMOKINE AND CYTOKINE DELIVERY BY MESENCHYMAL STEM CELL [patent_app_type] => utility [patent_app_number] => 18/005166 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656140 [patent_doc_number] => 20210052776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => MESENCHYMAL STEM CELLS OR STROMAL CELLS HARBORING MODIFIED RNAS ENCODING VEGF AND BMP POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/918979 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361326 [patent_doc_number] => 20200318077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => METHOD TO REPRODUCE CIRCADIAN RHYTHMS ON A MICROFLUIDIC CHIP [patent_app_type] => utility [patent_app_number] => 16/905987 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241972 [patent_doc_number] => 20210361715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => USE OF EXOSOME DERIVED FROM MESENCHYMAL STEM CELLS CO-CULTURED WITH MELATONIN IN PREVENTION AND TREATMENT OF CHRONIC KIDNEY DISEASE [patent_app_type] => utility [patent_app_number] => 16/906839 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541271 [patent_doc_number] => 20200407684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => METHOD FOR THE SELECTIVE DIFFERENTIATION INTO M1 MACROPHAGES [patent_app_type] => utility [patent_app_number] => 16/898072 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020985 [patent_doc_number] => 20220372484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => FPR2 RECEPTOR AGONIST APTAMERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/618104 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17759960 [patent_doc_number] => 20220233572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 [patent_app_type] => utility [patent_app_number] => 17/611497 [patent_app_country] => US [patent_app_date] => 2020-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16970680 [patent_doc_number] => 11066643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Natural killer cells with enhanced viability, proliferation and cytotoxicity following cryopreservation [patent_app_type] => utility [patent_app_number] => 15/931393 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 10 [patent_no_of_words] => 3533 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931393 [rel_patent_id] =>[rel_patent_doc_number] =>)